Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Standard
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. / Heathcote, E Jenny; Marcellin, Patrick; Buti, Maria; Gane, Edward; Man, De; Robert, A; Krastev, Zahary; Germanidis, George; Lee, Samuel S; Flisiak, Robert; Kaita, Kelly; Manns, Michael; Kotzev, Iskren; Buggisch, Peter; Buggisch, Peter; Weilert, Frank; Kurdas, Oya Ovunc; Shiffman, Mitchell L; Trinh, Huy; Gurel, Selim; Snow-Lampart, Andrea; Borroto-Esoda, Katyna; Mondou, Elsa; Anderson, Jane; Sorbel, Jeff; Rousseau, Franck.
in: GASTROENTEROLOGY, Jahrgang 140, Nr. 1, 1, 2011, S. 132-143.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
AU - Heathcote, E Jenny
AU - Marcellin, Patrick
AU - Buti, Maria
AU - Gane, Edward
AU - Man, De
AU - Robert, A
AU - Krastev, Zahary
AU - Germanidis, George
AU - Lee, Samuel S
AU - Flisiak, Robert
AU - Kaita, Kelly
AU - Manns, Michael
AU - Kotzev, Iskren
AU - Buggisch, Peter
AU - Buggisch, Peter
AU - Weilert, Frank
AU - Kurdas, Oya Ovunc
AU - Shiffman, Mitchell L
AU - Trinh, Huy
AU - Gurel, Selim
AU - Snow-Lampart, Andrea
AU - Borroto-Esoda, Katyna
AU - Mondou, Elsa
AU - Anderson, Jane
AU - Sorbel, Jeff
AU - Rousseau, Franck
PY - 2011
Y1 - 2011
N2 - Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir dipivoxil in treatment of chronic hepatitis B through 48 weeks. We evaluated long-term efficacy and safety of TDF monotherapy in patients with chronic hepatitis B who were positive or negative for hepatitis B e antigen (HBeAg(+) or HBeAg(-)).
AB - Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir dipivoxil in treatment of chronic hepatitis B through 48 weeks. We evaluated long-term efficacy and safety of TDF monotherapy in patients with chronic hepatitis B who were positive or negative for hepatitis B e antigen (HBeAg(+) or HBeAg(-)).
KW - Adult
KW - Biopsy
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Adolescent
KW - Young Adult
KW - Randomized Controlled Trials as Topic
KW - Treatment Outcome
KW - Follow-Up Studies
KW - Antiviral Agents/therapeutic use
KW - Alanine Transaminase/blood
KW - Adenine/analogs & derivatives/therapeutic use
KW - DNA, Viral/drug effects
KW - Drug Resistance, Viral/drug effects
KW - Hepatitis B e Antigens/analysis
KW - Hepatitis B virus/drug effects
KW - Hepatitis B, Chronic/drug therapy/virology
KW - Phosphonic Acids/therapeutic use
KW - Virus Replication/drug effects
KW - Adult
KW - Biopsy
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Adolescent
KW - Young Adult
KW - Randomized Controlled Trials as Topic
KW - Treatment Outcome
KW - Follow-Up Studies
KW - Antiviral Agents/therapeutic use
KW - Alanine Transaminase/blood
KW - Adenine/analogs & derivatives/therapeutic use
KW - DNA, Viral/drug effects
KW - Drug Resistance, Viral/drug effects
KW - Hepatitis B e Antigens/analysis
KW - Hepatitis B virus/drug effects
KW - Hepatitis B, Chronic/drug therapy/virology
KW - Phosphonic Acids/therapeutic use
KW - Virus Replication/drug effects
M3 - SCORING: Journal article
VL - 140
SP - 132
EP - 143
JO - GASTROENTEROLOGY
JF - GASTROENTEROLOGY
SN - 0016-5085
IS - 1
M1 - 1
ER -